December 6, 2023


Expect exquisite business

Destiny Pharma – Neil Clark, CEO (AIM:DEST) One2One Virtual Forum 10th December 2021

Future Pharma PLC (Aim:DEST) (Future Pharma PLC (Aim:DEST)) is a clinical phase, revolutionary biotechnology enterprise centered on the development of novel medications that can avoid daily life-threatening infections. The firm’s pipeline has novel microbiome-based mostly biotherapeutics and XF drug clinical assets such as NTCD-M3, a Stage 3 prepared treatment for the prevention of C. difficile an infection (CDI) recurrence which is the main cause of clinic acquired infections in the US. Destiny’s pipeline also consists of XF-seventy three nasal gel, which has not long ago completed a favourable Stage 2b clinical trial concentrating on the prevention of publish-surgical staphylococcal clinic infections such as MRSA. The enterprise is also co-developing SPOR-COV, a novel, biotherapeutic solution for the prevention of COVID-19 and other viral respiratory infections.